Abstract N-[2-Methyl-5-(triazol-1-yl) phenyl] pyrimidin-2-amine derivatives were synthesized and evaluated in vitro for their potential use as inhibitors of Bcr-Abl. The design is based on the bioisosterism between the 1, 2, 3-triazole ring and the amide group. The synthesis involves a copper (I)-catalyzed azide–alkyne cycloaddition (CuAAC) as the key step, with the exclusive production of anti-(1, 4)-triazole derivatives. One of the compounds obtained ...
